- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05190185
A Clinical Trial of TAA06 Injection in Advanced Solid Tumors
December 29, 2021 updated by: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
B7-H3 (also known as CD276) is widely expressed on the surface of a variety of malignancies solid tumors, while it rarely or even doesn't express on normal tissues.
Therefore, B7-H3 is an ideal target for chimeric antigen receptor (CAR) T cells therapy.
TAA06 injection is a CAR T injection targeting B7-H3.
This is a phase I clinical study with the primary objective of evaluating the safety and tolerability of TAA06 injection in subjects with TAA06-positive advanced solid tumors.
The secondary objectives are as follows: to evaluate the distribution, proliferation and persistence of B7-H3-targeted CAR T cells after injection of TAA06 in subjects; to preliminarily evaluate the efficacy of TAA06 injection in subjects with TAA06-positive advanced solid tumor.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhiyu Wang, Doctor
- Phone Number: +86-138 3119 5070
- Email: drwangzhiyu@hebmu.edu.cn
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215125
- Recruiting
- PersonGen BioTherapeutics(Suzhou) Co., Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- (1) Aged 18 to 70 years old (inclusive), male or female;
- (2) Expected survival time ≥ 12 weeks;
- (3) ECOG performance status of 0-1;
- (4) It is clearly diagnosed by pathology to be any of the following tumor types: malignant melanoma, lung cancer or colorectal cancer, and the positive rate of TAA06 expression in tumor tissues is ≥1% after immunohistochemical detection;
- (5) Subjects whose standard treatment methods are ineffective (eg: relapse after surgery, disease progress after treatment with chemotherapy, radiotherapy or targeted drugs);
- (6) According to the curative effect evaluation standard for solid tumors (RECIST 1.1), at least one measurable lesion (the longest diameter of the solid lesion ≥ 10mm, or the short diameter of the lymph node lesion ≥ 15mm);
- (7) The main organ function is normal (white blood cell count ≥3×109/L, neutrophil count ≥1.5×109/L, hemoglobin ≥8.5g/dL, platelet count ≥80×109/L, lymphocyte count at 1×109/L (inclusive) ~ 4×109/L (inclusive));
(8) Liver and kidney function, heart and lung function meet the following criteria:
- Urea (Urea) and serum creatinine≤1.5×ULN;
- Left ventricular ejection fraction ≥50%;
- Baseline blood oxygen saturation ≥ 94%;
- Total bilirubin≤1.5×ULN; ALT and AST≤2.5×ULN;
- (9) The subjects or his legal representative can fully understand the significance and risks of this trial and has signed informed consents.
Exclusion Criteria:
- (1) Subjects with a history of immunodeficiency or autoimmune diseases (including but not limited to rheumatoid joint disease, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes, etc.); with graft-versus-host disease (GVHD) , Or those who need to use immunosuppressive agents;
- (2) Subjects with other type of malignant tumors within 5 years prior to screening;
- (3) Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood hepatitis B virus (HBV) DNA titer detection not within the normal reference range; positive for hepatitis C virus (HCV) antibody and peripheral blood hepatitis C virus (HCV) RNA; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis test;
- (4) Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ III), severe arrhythmia;
- (5) Unstable systemic diseases judged by the investigator: including but not limited to serious liver, kidney or metabolic diseases requiring drug treatment;
- (6) Within 7 days prior to screening, there are active or uncontrollable infections requiring systemic therapy (except for mild genitourinary infection and upper respiratory tract infection);
- (7) Pregnant or lactating women, and female subjects who plan to become pregnant within 1 year after cell infusion or male subjects whose partners plan to become pregnant within 1 year after cell infusion;
- (8) Subjects who have received CAR-T therapy or other gene-modified cell therapy prior to screening;
- (9) Subjects who are receiving systemic steroid therapy within 7 days prior to screening or need long-term use of systemic steroid therapy during treatment as judged by the investigator (except for inhalation or topical use);
- (10) Subjects with more than a moderate amount of ascites, or after conservative medical treatment (such as diuresis, sodium restriction, excluding ascites drainage) for 2 weeks, the ascites still shows a progressive increase;
- (11) Conditions not eligible for cell preparation as judged by the investigator;
- (12) Other conditions considered unsuitable for enrollment by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TAA06 injection
T cell injection targeting B7-H3 chimeric antigen receptor
|
The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106~1×108 CAR-T/kg.
And the subjects will be administered once.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the safety after B7-H3 chimeric antigen receptor T cells infusion (Safety)
Time Frame: 3 months
|
Incidence and treatment-relativity of adverse events assessed by NCI CTCAE v5.0.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate anti-tumor activity (overall response rate)
Time Frame: 6 months
|
Rate of participants achieving a complete response (CR) or partial response (PR).
|
6 months
|
To evaluate anti-tumor activity (disease control rate)
Time Frame: 3 months
|
Rate of participants achieving a complete response (CR) or partial response (PR) or stable disease (PD).
|
3 months
|
To evaluate anti-tumor activity (duration of response)
Time Frame: About 2 years
|
Defined as the time from the first tumor assessment of CR or PR to the first assessment of disease progression (PD) or death from any cause.
|
About 2 years
|
To evaluate anti-tumor activity (Progression Free Survival)
Time Frame: About 2 years
|
Defined as the time from the date of study enrollment to the time when the investigator judges that imaging disease progression or death from any cause occurs.
|
About 2 years
|
To evaluate anti-tumor activity (overall survival)
Time Frame: About 2 years
|
Defined as the time from start of the random beginning to death (due to any cause).
|
About 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 1, 2021
Primary Completion (ANTICIPATED)
December 1, 2023
Study Completion (ANTICIPATED)
December 1, 2023
Study Registration Dates
First Submitted
December 29, 2021
First Submitted That Met QC Criteria
December 29, 2021
First Posted (ACTUAL)
January 13, 2022
Study Record Updates
Last Update Posted (ACTUAL)
January 13, 2022
Last Update Submitted That Met QC Criteria
December 29, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PG-CART-TAA06-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma, Lung Cancer, or Colorectal Cancer
-
OncoHost Ltd.RecruitingStage IV Non-small Cell Lung Cancer | Stage III Malignant Melanoma | Stage IV Small Cell Lung Cancer | Stage IV Malignant MelanomaUnited States, Israel, United Kingdom, Germany, Spain
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedStage IV Lung Cancer | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Malignant Female Reproductive System Neoplasm | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Liver | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic...United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Sarcoma | Lymphoma | Leukemia | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Thyroid Gland Carcinoma | Clinical... and other conditionsUnited States
-
Deciphera Pharmaceuticals LLCRecruitingMelanoma | Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Pancreatic Ductal AdenocarcinomaUnited States
-
University of California, San FranciscoBristol-Myers Squibb FoundationCompletedStage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Malignant Neoplasm | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
-
Herlev HospitalActive, not recruitingNon Small Cell Lung Cancer Metastatic | Malignant Melanoma, Metastatic | Bladder Urothelial Carcinoma, MetastaticDenmark
-
EMD SeronoSanofiCompletedMelanoma | Breast Cancer | Colorectal Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid TumorUnited States, Italy, Spain
-
Hoffmann-La RocheCompletedMalignant Melanoma, CancerHungary
Clinical Trials on TAA06 injection
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Tianjin Medical University Cancer Institute and Hospital; Shandong Cancer Hospital...RecruitingB7-H3-positive Relapsed/ Refractory NeuroblastomaChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated
-
National Taiwan University HospitalCompleted